Monitoring of Stem Cell Engraftment in Arthritic Joints with MR Imaging

利用 MR 成像监测关节炎关节中的干细胞移植

基本信息

批准号：
8892880
负责人：
Heike Elizabeth Daldrup-Link
金额：
$ 16.05万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-15 至 2017-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8892880
关键词：
Absence of pain sensation Address Adolescent Adrenal Cortex Hormones Adult Adverse effects Affect Anaphylaxis Anemia Arthralgia Arthritis Biochemistry Blood Blood Transfusion Body Weight Bone Marrow Bone Marrow Transplantation Bone Regeneration Bone necrosis Cancer Survivor Cell Therapy Cells Childhood Childhood Leukemia Childhood Lymphoma Clinical Clinical Data Clinical Trials Collaborations Contrast Media Cortisone Coupled Data Defect Detection Diagnosis Dose Early Diagnosis Engraftment Evolution FDA approved Failure Femur Future Goals Grant Harvest Hematology Image Imaging Device Imaging technology Investigation Iron Joints Label Lead Magnetic Resonance Imaging Malignant Neoplasms Measures Mediating Mesenchymal Mesenchymal Stem Cells Monitor Morbidity - disease rate Narcotics Necrosis Operative Surgical Procedures Orthopedic Surgery procedures Orthopedics Outcome Parents Pathogenesis Patient Monitoring Patients Pediatric Hematology Pediatric Oncologist Pediatric Oncology Pediatrics Process Reaction Repeat Surgery Replacement Arthroplasty Reporting Research Personnel Safety Signal Transduction Source Stem cell transplant Stem cells Stromal Cells Surgeon Survivors T2 weighted imaging Techniques Technology Testing Translations Transplantation United States base bench to bedside bone cellular imaging childhood cancer survivor ferumoxytol graft failure image guided therapy imaging agent implantation in vivo interdisciplinary collaboration intravenous administration iron supplement joint function leukemia/lymphoma novel osteochondral tissue particle patient population professor public health relevance reconstitution repaired stem cell therapy success tool uptake

项目摘要

DESCRIPTION (provided by applicant): This BIRT project should integrate novel cellular imaging technologies, developed through our parental R01 project, with an advanced understanding of the pathogenesis of corticosteroid-induced osteonecrosis through our new co-investigator Dr. Sakamoto (Professor of Pediatrics) and new stem cell therapies for osteonecrosis, developed by our new co-investigator Dr. Goodman (Professor of Orthopedic Surgery). Therapy-induced osteonecrosis is a major source of morbidity in patients with leukemia and lymphoma. Recently, surgical core decompression coupled with delivery of bone marrow derived stem cells has shown promising results to repair the necrotic bone. The overall goal of our BIRT project is to utilize cell tracking tools, developed by our parent R01 grant, for n vivo detection of stem cell transplants in osteonecrotic bone and to correlate stem cell engraftment with bone regeneration outcomes. In a bench-to-bedside approach, we propose to use the FDA-approved iron supplement ferumoxytol to label mesenchymal stem cells (MSC) in the bone marrow of patients before a decompression surgery, and then follow the engraftment of bone marrow derived MSC after transplantation into osteonecrotic bone with serial MR imaging studies. We hypothesize that MR tracking of stem cells in osteonecrotic bone will enable differentiation of successful and failed cell therapies, as determined by reconstitution or progressive collapse of the affected bone. This will enable in vivo detection of complications of the engraftment process at a point in evolution, which is early enough for repeated surgeries or other corrective actions. Results will help to establish an immediately clinically applicable imaging test for early detection of MSC graft failure and generate important feasibility data for clinical translation of stem cell tracking technologies. Since we address a generalized novel concept of image-guided therapy, results might not only impact patients with stem cell transplants for osteonecrosis treatment but also patients with a variety of other stem cell therapies.

描述（通过应用程序提供）：这个BIRT项目应通过我们的父母R01项目开发的新型细胞成像技术，并通过我们的新共同研究人员Sakamoto博士（Pediatrics of Periatrics）和新的干细胞治疗师，由新的干细胞疗法（我们的新的COVESTIC）（我们的新的COVEST）（我们的新的COVEST）（我们的新的COVEST）（我们的新的COVEST）（我们的新的COVEST）（我们的新的COVEST）（我们的新的COVEST（我们的新的）（我们的新的COVEST）（我们的新的COVEST）（我们的新covest（我们的新的）（我们的新covest）（我们的新covest（我们的新）（我们外科手术）。治疗诱导的骨坏死是白血病和淋巴瘤患者发病的主要来源。最近，手术核心减压加上骨髓衍生的干细胞的递送，显示出有望修复坏死骨的结果。我们的BIRT项目的总体目标是利用由我们的父级R01赠款开发的细胞跟踪工具，用于n骨骨骼中干细胞移植的n个体内检测，并将干细胞的植入与骨骼再生结果相关联。 In a bench-to-bedside approach, we propose to use the FDA-approved iron supplement ferumoxytol to label mesenchymal stem cells (MSC) in the bone marrow of patients before a decompression surgery, and then follow the engraftment of bone marrow derived MSC after transplantation into osteonecrotic bone with serial MR imaging studies.我们假设，通过重构或受影响骨的逐渐崩溃确定，骨质细胞骨中干细胞的MR跟踪将能够区分成功和失败的细胞疗法。这将使在进化点的体内检测植入过程的并发症，这已经足够早，可以重复手术或其他纠正措施。结果将有助于建立立即临床适用的成像测试，以早日检测MSC移植失败，并为干细胞跟踪技术的临床翻译生成重要的可行性数据。由于我们谈到了图像引导疗法的广义新颖概念，因此结果不仅可能影响干细胞移植的截至治疗的患者，而且还会影响其他多种干细胞疗法的患者。